3Akamatsu H,Terashima M,Loike T,et al.Staging of primary lung cancer by computed tomography-guided percutaneous needle cytology of mediastinal lymph nodes[J].Ann Thorac Surg,1996,62(2):352-355. 被引量：1
4Larsen SS,Krasnik M,Vilmann P,et al.Endobronchial ultrasonography guided biopsy of mediasetina] lesions has a major impact on patient management[J].Thorax,2002,57 (2):98-103. 被引量：1
5Bakheet SM,Saleem M,Powe.],et al.F-18 fluorodeoxyglucose chest uptake in lung inflammation and infection[J].Clin NuclMed,2000,25 (4):273. 被引量：1
6Cohade C,Osman M,Pannu HK,et al.Uptake in supraclavicular area fat ("USA-Fat"):description on 18F-FDG PET-CT[J].J Nucl Med,2003,44(2):170-176. 被引量：1
7Ahuja V,Coleman RE,Herdon J,et al.The prognostic significance of flurodeoxy-glucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma[J].Cancer,1998,83(5):918. 被引量：1
8Van Waarde A,et al.Selectivity of 18F-FLT and 18F-FDG for differentiating tumor from inflammation in a rodent model[J].J Nucl Med,2004,45:695-700. 被引量：1
3Coleman RE.PET in lung cancer[J]. J Nucl Med,1999,40:814-820. 被引量：1
4Dietlein M, Weber K, Gandjour A, et al. Cost-effectiveness of FDG-PET for the management of solitary pulmonary nodules: a decision analysis based on cost reimbursement in Germany[J]. Eur J Nucl Med, 2000,27:1441-1456. 被引量：1
5Smith TAO. FDG uptake, tumor characteristic and response to therapy: a review[J]. Nucl Med Commun,1998,9:7-105. 被引量：1
6Zhuang H, Pourdehnad M, Lambright ES, et al. Dual time point 18F-FDG imaging for differentiating malignant from inflammatory processes[J]. J Nucl Med, 2001,2:1412-1417. 被引量：1
7Lowe VJ, Hoffman JM, Delong DM, et al. Semiquantitative and visual analysis of FDG PET images in pulmonary abnormalities[J]. J Nucl Med, 1994,35:1771-1776. 被引量：1
8Goo JM, Zm JG, Do KH, et al. Pulmonary tubercuculom a evaluated by means of FDG PET: finding in 10 cases[J]. Radiology, 2000,216:177-181. 被引量：1
9Keyes JM, SUV: Standard uptake or silly useless value[J]? J Nucl Med, 1995,36:1836-1839. 被引量：1
10Coleman RE. Is quantitation necessary for oncological PET studies[J]? Eur J Med, 2002,29:133-135. 被引量：1
3Little R,Rubin D.Statistical analysis with missing data.New York:John wiley and Sons,1987,1-371. 被引量：1
4Greenes RA,Begg CB.Assessment of diagnostic technologies:Methodology for unbiased estimation from samples of selective verified patients.Invest.Radio,1985,20(7):751-756. 被引量：1
5Zhou XH.Maximum likelihood estimators of sensitivity and specificity corrected for verification bias.Communications in statistics-Theory and methods,1993,22(11):3177-3198. 被引量：1
6Zhou XH.Correcting for verification bias in studies of a diagnostic test's accuracy.Statistical Methods in Medical Research,1998,7(4):337-353. 被引量：1
7Coleman RE.PET in lung cancer.J Nucl Med,1999,40(5):814-820. 被引量：1
8Alonzo TA.Verification bias-corrected estimators of the relative true and false positive rates of two binary screening testes.Statistics in Medicine,2005,24(3):403-417. 被引量：1
9Shig SS,Lee KS,Kim QT,et al.Non-small cell lung cancer:prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging.Radiology,2005,236(3):1011-1019. 被引量：1
